Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.

Jiang, Shiyu; Qin, Yan; Jiang, Hongxin; Liu, Biao; Shi, Jianming; Meng, Fanlu; Liu, Peng; Yang, Jianliang; Yang, Sheng; He, Xiaohui; Zhou, Shengyu; Gui, Lin; Liu, Hao; Lin, Jing; Han-Zhang, Han; Shi, Yuankai

Jiang, Shiyu; Qin, Yan; Jiang, Hongxin; Liu, Biao; Shi, Jianming; Meng, Fanlu; Liu, Peng; Yang, Jianliang; Yang, Sheng; He, Xiaohui; Zhou, Shengyu; Gui, Lin; Liu, Hao; Lin, Jing; Han-Zhang, Han; Shi, Yuankai.

Afiliación

Jiang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Qin Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Jiang H; Department of Medical Oncology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Liu B; Department of Pathology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Shi J; Department of Medical Oncology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Meng F; Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
Liu P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Yang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Yang S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
He X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Zhou S; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Gui L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Liu H; Burning Rock Biotech, Guangzhou, China.
Lin J; Burning Rock Biotech, Guangzhou, China.
Han-Zhang H; Burning Rock Biotech, Guangzhou, China.
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Int J Cancer ; 147(9): 2611-2620, 2020 11 01.

Article en En | MEDLINE | ID: mdl-32399964

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/farmacología; Biomarcadores de Tumor/genética; Resistencia a Antineoplásicos/genética; Linfoma de Células B Grandes Difuso/tratamiento farmacológico; Adolescente; Adulto; Anciano; Anciano de 80 o más Años; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Niño; China/epidemiología; Ciclofosfamida/farmacología; Ciclofosfamida/uso terapéutico; Variaciones en el Número de Copia de ADN; Análisis Mutacional de ADN; Progresión de la Enfermedad; Doxorrubicina/farmacología; Doxorrubicina/uso terapéutico; Femenino; Estudios de Seguimiento; Amplificación de Genes; Humanos; Estimación de Kaplan-Meier; Linfoma de Células B Grandes Difuso/genética; Linfoma de Células B Grandes Difuso/mortalidad; Masculino; Persona de Mediana Edad; Mutación; Factor 88 de Diferenciación Mieloide/genética; Prednisona/farmacología; Prednisona/uso terapéutico; Proteínas Proto-Oncogénicas c-bcl-2/genética; Estudios Retrospectivos; Rituximab/farmacología; Rituximab/uso terapéutico; Proteína p53 Supresora de Tumor/genética; Vincristina/farmacología; Vincristina/uso terapéutico; Adulto Joven

Palabras clave

TP53 mutation; diffuse large B-cell lymphoma; refractory; relapse

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Linfoma de Células B Grandes Difuso / Resistencia a Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 País/Región como asunto: Asia Idioma: En Revista: Int J Cancer Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google